Redwood Pharma
Redwood Pharma develops ophthalmic drugs in areas where medical need is especially great.
This is an approach exemplified by our very first project. RP101 treats chronic dry eyes in post-menopausal women. Something that is possible thanks to our drug delivery platform IntelliGel, which controls the release of active substances. The platform also supports improved dosages of other established drugs.
Dry eye disease (DED) offers enormous potential. A total of some 344 million people are affected, equivalent to a global market of USD 3.1 billion. And the market is expected to grow, not least due to the lack of effective treatments.
This is something we want to change. Our strategy is to sign licence agreements with drug companies that will manufacture and market products on the global market.
Redwood Pharma AB (publ.) is listed on the Nasdaq First North Growth Market (ticker: REDW, ISIN: SE008294789).
in Feb. 12 2012 with HQ in Stockholm, Sweden
Development of new opthalmic medicines
Nasdaq First North Growth Market (REDW)
Topical therapy for Dry Eye Disease
of external expertise in production, quality and regulatory organizations
IntelliGel hydrogel drug delivery platform
Board of Directors
Ulf Björklund
Chairman of the Board (since 2023), Chief Medical Officer (since 2016)
Providing consulting services as Chief Medical Officer since 2016.
Born: 1956.
Education: Pharmacist at Uppsala University.
Other assignments: CEO and board member of UB-Consulting AB, Chairman of the Board of Lipum AB and Stayble Therapeutics AB.
Holdings: 163,647 shares (0.15%).
Independence in relation to the company and company management: No
Independence in relation to major shareholders: Yes
Tom Rönnlund
Board member since 2023
Education: MBA from Stockholm University.
Other assignments: CCO of Surgify Medical Oy and Board member of Bonnier Healthcare and Prostalund AB.
Holdings: 0 shares (0%)
Independence in relation to the company and company management: YesIndependence in relation to major shareholders: Yes
Håkan Magnusson
Board member since 2023
Education: MBA in International Business Administration from Lund University.
Other assignments: Interim CEO of Lectica Group.
Holdings: 0 shares (0%)
Independence in relation to the company and company management: Yes
Independence in relation to major shareholders: Yes
Martin Vidaeus
Board member and CEO since 2012
Born: 1966.
Education: MBA from New York University, USA, and Bachelor of Science in Chemical Engineering from University of Maryland, College Park, USA.
Other assignments:
Shareholding: 2,462,449 shares (2.3%).
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes
Management
Martin Vidaeus
Board member and CEO since 2012
Born: 1966.
Education: MBA from New York University, USA, and Bachelor of Science in Chemical Engineering from University of Maryland, College Park, USA.
Other assignments:
Shareholding: 2,462,449 shares (2.3%).
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes
Hans Ageland
Chief Operating Officer since 2012
Born: 1961.
Education: Master of Science in Biochemistry from KTH.
Other assignments: Deputy board member Ateljé Grön AB and deputy board member Daniel & Sebastian Byggentreprenad AB.
Shareholding: 407,109 shares (0.38%).
Independence in relation to the company and its management: NoIndependence in relation to major shareholders: Yes
Ulf Björklund
Chief Medical Officer since 2016
Consultant as Chief Medical Officer since 2016.
Born: 1956.
Education: Pharmacist at Uppsala University.
Other assignments: CEO and board member UB-consulting AB, Chairman of the Board Lipum AB and Chairman of the Board Stayble Therapeutics AB.
Shareholding: 18,183 shares (0,17%)
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes
Peter Rooslien
Chief Financial Officer since 2016
Providing consulting services as CFO since in 2016.
Born: 1956.
Education: Master of Business Administration from Stockholm University.
Other assignments: Chairman of the Board RochS Sifferkontoret AB and board member in Rooslien Ekonomikonsult AB.
Innehav: Peter Rooslien saknar innehav i Bolaget.
Independence in relation to the company and its management: No
Independence in relation to major shareholders: Yes